Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06831825 · ClinicalTrials.gov registry record · Phase 1

Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure

A Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by YAP Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06831825 is a Phase 1 study of Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by YAP Therapeutics. The registered enrollment target is 24 participants, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06831825, a Phase 1 study of Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by YAP Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF). Ischemic heart failure, often resulting from a prior heart attack, leads to poor heart function and quality of life. Current treatments are limited, and there is an urgent need for new therapies. YAP101 works by delivering a gene therapy using a specialized vector to heart cells, targeting a pathway involved in heart repair. By temporarily activating heart muscle regeneration, YAP101 aims to restore damaged tissue, reduce scarring, and improve the heart's pumping ability. The study will enroll participants who will receive a one-time dose of YAP101 via a minimally invasive cardiac injection. Researchers will monitor participants over 12 months to assess safety and changes in heart function, exercise tolerance, and quality of life.

Conditions Studied

Heart Failure With Reduced Ejection Fraction

Interventions

  • COMBINATION_PRODUCT YAP101 (AAV9-Sav-shRNA)

Study Locations (1)

Texas

  • Texas Heart Institute - Houston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-04-23
Est. Completion 2027-06
Phase Phase 1

Sponsor

YAP Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06831825

The ClinicalTrials.gov registry entry for NCT06831825 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (99% lower). The listed sponsor is YAP Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which YAP101 (AAV9-Sav-shRNA) is the first listed.

NCT06831825 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06831825 about?

NCT06831825 is a clinical study titled "Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure". This clinical trial investigates the safety and preliminary effectiveness of YAP101, a gene therapy designed to improve heart function in adults with ischemic heart failure and reduced ejection fraction (HFrEF). Ischemic heart failure, often resulting from a prior heart attack, leads to poor heart f...

What is the current status of trial NCT06831825?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-23. Estimated completion is 2027-06.

What conditions does trial NCT06831825 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.

What interventions are being tested in trial NCT06831825?

The interventions under investigation include: YAP101 (AAV9-Sav-shRNA) (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06831825?

This trial is sponsored by YAP Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06831825 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Reduced Ejection Fraction

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.